FTSE 100: Index falls as earnings results weigh; pound below $1.33, Bodycote soars
BANGKOK - NewGenIvf Group Limited (NASDAQ: NIVF), an Asian fertility services provider, has announced a reverse stock split of its shares at a ratio of one for ten. The adjustment will take effect at the start of trading on May 5, 2025, on the Nasdaq Global Market. The reverse split aims to reduce the number of NewGenIvf’s outstanding Class A Ordinary Shares from approximately 7.3 million to around 730,282. The announcement comes as the company’s stock, currently trading at $0.33, has declined nearly 99% over the past year. InvestingPro analysis indicates the stock is currently trading below its Fair Value.
In this consolidation, every ten existing Class A Ordinary Shares will be converted into one post-Reverse Stock Split Class A Ordinary Share. Shareholders who would receive a fractional share from the split will instead be issued one full post-split share. The company’s options, warrants, and other convertible securities will also be adjusted in accordance with the reverse split, with terms rounded to the nearest whole share. With a market capitalization of just $0.49 million and significant debt burden, the company faces financial challenges reflected in its weak overall Financial Health Score.
NewGenIvf specializes in providing comprehensive fertility services, including infertility treatments, egg and sperm donation, and surrogacy, where legally permitted. The company operates clinics in Thailand, Cambodia, and Kyrgyzstan. NewGenIvf’s management team has over a decade of experience in the fertility industry. Despite generating annual revenue of $5.43 million, the company is quickly burning through cash, according to InvestingPro analysis, which has identified 14 additional key investment factors for this stock.
The press release includes forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, outlining the company’s expectations for its future operations and financial performance. However, these statements are subject to various risks and uncertainties that could cause actual results to differ.
Investors are reminded that this news is based on a press release statement and should consider the risks and uncertainties described in NewGenIvf’s filings with the SEC, which may impact the company’s future results.
In other recent news, NewGenIvf Group Limited has secured $5.2 million in strategic funding to support its expansion into the United Arab Emirates, specifically for a new fertility clinic in Dubai. This funding is part of a broader initiative to raise up to $30.8 million, with $2 million obtained through a Securities Purchase Agreement. Meanwhile, NewGenIvf has terminated its merger agreement with European Wellness Investment Holdings Limited due to the latter’s failure to meet financial statement delivery deadlines. The proposed merger would have resulted in EWIHL acquiring a majority stake in NewGen. Despite this setback, NewGen remains focused on its core business strategies and growth, including the introduction of new services. Additionally, the company has regained compliance with Nasdaq’s minimum bid price requirement, maintaining a share price of $1.00 or higher for ten consecutive business days. In line with this, NewGen has transferred its listing from the Nasdaq Global Market to the Nasdaq Capital Market. These developments reflect NewGen’s ongoing efforts to enhance its market position and shareholder value.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.